Eisai doubles down on dementia

Scientists are at an impasse in developing new dementia therapies. So Japanese drug maker Eisai, recovering from the failure of its Alzheimer’s drug, aducanumab, is launching an incubator to nurture startups focused on such neurodegenerative diseases. 

The Eisai Incubator for NeuroDiscovery — e-IND for short — has actually been in development for the past year. It’ll be located in Cambridge, where Eisai is relocating its Massachusetts-based research staff to focus on the link between inflammation and diseases of the brain. 

Read more.